250 related articles for article (PubMed ID: 24627526)
1. How we prevent and treat differentiation syndrome in patients with acute promyelocytic leukemia.
Sanz MA; Montesinos P
Blood; 2014 May; 123(18):2777-82. PubMed ID: 24627526
[TBL] [Abstract][Full Text] [Related]
2. [Coagulopathy and differentiation syndrome: the main complications of the initial treatment of acute promyelocytic leukemia].
Korístek Z; Zák P
Vnitr Lek; 2008; 54(7-8):745-50. PubMed ID: 18780573
[TBL] [Abstract][Full Text] [Related]
3. Differentiation syndrome in patients with acute promyelocytic leukemia.
Rogers JE; Yang D
J Oncol Pharm Pract; 2012 Mar; 18(1):109-14. PubMed ID: 21364078
[TBL] [Abstract][Full Text] [Related]
4. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial.
Burnett AK; Russell NH; Hills RK; Bowen D; Kell J; Knapper S; Morgan YG; Lok J; Grech A; Jones G; Khwaja A; Friis L; McMullin MF; Hunter A; Clark RE; Grimwade D;
Lancet Oncol; 2015 Oct; 16(13):1295-305. PubMed ID: 26384238
[TBL] [Abstract][Full Text] [Related]
5. [Acute kidney failure in differentiation syndrome: a possible complication during therapy with differentiating agents for acute promyelocytic leukemia. A case report].
Di Micco L; Mirenghi F; Morelli E; De Simone E
G Ital Nefrol; 2019 Jul; 36(4):. PubMed ID: 31373469
[TBL] [Abstract][Full Text] [Related]
6. Differentiation syndrome in acute promyelocytic leukaemia.
Stahl M; Tallman MS
Br J Haematol; 2019 Oct; 187(2):157-162. PubMed ID: 31410848
[TBL] [Abstract][Full Text] [Related]
7. Recurrent acute myopericarditis without effusion during ATRA induction and ATO salvage of APL: a variant form of the differentiation syndrome?
Vassilakopoulos TP; Asimakopoulos JV; Plata E; Kelepesis G; Petevi K; Koutsi C; Papageorgiou L; Tsaftaridis P; Angelopoulou MK; Konstantopoulos K; Meletis J
Leuk Lymphoma; 2017 Jul; 58(7):1743-1746. PubMed ID: 27919176
[No Abstract] [Full Text] [Related]
8. Retinoic acid syndrome induced by arsenic trioxide in treating recurrent all-trans retinoic acid resistant acute promyelocytic leukemia.
Che-Pin Lin ; Huang MJ; Chang IY; Lin WY; Sheu YT
Leuk Lymphoma; 2000 Jun; 38(1-2):195-8. PubMed ID: 10811463
[TBL] [Abstract][Full Text] [Related]
9. Multidisciplinary corroboration in differentiation syndrome: a case report.
Sarkar S; Ghosh P; Gehani A; Ghara N; Bhattacharyya P
J Med Case Rep; 2021 May; 15(1):226. PubMed ID: 33947461
[TBL] [Abstract][Full Text] [Related]
10. [An analysis of the therapeutic effects and reactions in treating acute promyelocytic leukemia with intravenous arsenic trioxide or all-trans retinoic acid].
Zhang X; Yang L; Qiao Z
Zhonghua Nei Ke Za Zhi; 1999 Feb; 38(2):113-5. PubMed ID: 11798639
[TBL] [Abstract][Full Text] [Related]
11. Severe Wernicke encephalopathy and acute pancreatitis due to all-trans-retinoic acid and arsenic trioxide during treatment of acute promyelocytic leukaemia: a case report.
Jiang Y; Ji L
J Int Med Res; 2020 Sep; 48(9):300060520959487. PubMed ID: 32993392
[TBL] [Abstract][Full Text] [Related]
12. Leukocytosis and the retinoic acid syndrome in patients with acute promyelocytic leukemia treated with arsenic trioxide.
Camacho LH; Soignet SL; Chanel S; Ho R; Heller G; Scheinberg DA; Ellison R; Warrell RP
J Clin Oncol; 2000 Jul; 18(13):2620-5. PubMed ID: 10893295
[TBL] [Abstract][Full Text] [Related]
13. Current management of newly diagnosed acute promyelocytic leukemia.
Cicconi L; Lo-Coco F
Ann Oncol; 2016 Aug; 27(8):1474-81. PubMed ID: 27084953
[TBL] [Abstract][Full Text] [Related]
14. Acute promyelocytic leukemia: where did we start, where are we now, and the future.
Coombs CC; Tavakkoli M; Tallman MS
Blood Cancer J; 2015 Apr; 5(4):e304. PubMed ID: 25885425
[TBL] [Abstract][Full Text] [Related]
15. Acute lung injury induced by arsenic trioxide in a patient with refractory myelodysplastic syndrome.
Hassaballa HA; Lateef OB; Silver MR; Balk RA
J Crit Care; 2005 Mar; 20(1):111-3. PubMed ID: 16015525
[TBL] [Abstract][Full Text] [Related]
16. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia.
Lo-Coco F; Avvisati G; Vignetti M; Thiede C; Orlando SM; Iacobelli S; Ferrara F; Fazi P; Cicconi L; Di Bona E; Specchia G; Sica S; Divona M; Levis A; Fiedler W; Cerqui E; Breccia M; Fioritoni G; Salih HR; Cazzola M; Melillo L; Carella AM; Brandts CH; Morra E; von Lilienfeld-Toal M; Hertenstein B; Wattad M; Lübbert M; Hänel M; Schmitz N; Link H; Kropp MG; Rambaldi A; La Nasa G; Luppi M; Ciceri F; Finizio O; Venditti A; Fabbiano F; Döhner K; Sauer M; Ganser A; Amadori S; Mandelli F; Döhner H; Ehninger G; Schlenk RF; Platzbecker U; ; ;
N Engl J Med; 2013 Jul; 369(2):111-21. PubMed ID: 23841729
[TBL] [Abstract][Full Text] [Related]
17. Meta-analysis of all-trans retinoic acid-linked arsenic trioxide treatment for acute promyelocytic leukemia.
Chen L; Wang J; Hu X; Xu X
Hematology; 2014 Jun; 19(4):202-7. PubMed ID: 24074286
[TBL] [Abstract][Full Text] [Related]
18. Arsenic: a new place?
Vincent PC
Pathology; 1999 May; 31(2):81-2. PubMed ID: 10399159
[No Abstract] [Full Text] [Related]
19. All-trans-retinoic acid and arsenic trioxide as initial therapy for acute promyelocytic leukemia.
Quezada G; Kopp L; Estey E; Wells RJ
Pediatr Blood Cancer; 2008 Jul; 51(1):133-5. PubMed ID: 18293388
[TBL] [Abstract][Full Text] [Related]
20. Arsenic trioxide and acute promyelocytic leukemia: clinical and biological.
Chen Z; Zhao WL; Shen ZX; Li JM; Chen SJ; Zhu J; Lallemand-Breittenbach V; Zhou J; Guillemin MC; Vitoux D; de Thé H
Curr Top Microbiol Immunol; 2007; 313():129-44. PubMed ID: 17217042
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
